83 related articles for article (PubMed ID: 35789445)
1. Trophoblast Cell Surface Antigen 2 gene (TACSTD2) expression in primary breast cancer.
Vidula N; Yau C; Rugo H
Breast Cancer Res Treat; 2022 Aug; 194(3):569-575. PubMed ID: 35789445
[TBL] [Abstract][Full Text] [Related]
2. Trop2: Jack of All Trades, Master of None.
Lenárt S; Lenárt P; Šmarda J; Remšík J; Souček K; Beneš P
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33187148
[TBL] [Abstract][Full Text] [Related]
3. Targeting Trop2 in solid tumors: a look into structures and novel epitopes.
Liu X; Li J; Deng J; Zhao J; Zhao G; Zhang T; Jiang H; Liang B; Xing D; Wang J
Front Immunol; 2023; 14():1332489. PubMed ID: 38179054
[TBL] [Abstract][Full Text] [Related]
4. Single-sEV profiling identifies the TACSTD2 + sEV subpopulation as a factor of tumor susceptibility in the elderly.
Ning N; Lu J; Li Q; Li M; Cai Y; Wang H; Li J
J Nanobiotechnology; 2024 May; 22(1):222. PubMed ID: 38698420
[TBL] [Abstract][Full Text] [Related]
5. Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates.
Ajkunic A; Sayar E; Roudier MP; Patel RA; Coleman IM; De Sarkar N; Hanratty B; Adil M; Zhao J; Zaidi S; True LD; Sperger JM; Cheng HH; Yu EY; Montgomery RB; Hawley JE; Ha G; Persse T; Galipeau P; Lee JK; Harmon SA; Corey E; Lang JM; Sawyers CL; Morrissey C; Schweizer MT; Gulati R; Nelson PS; Haffner MC
NPJ Precis Oncol; 2024 May; 8(1):104. PubMed ID: 38760413
[TBL] [Abstract][Full Text] [Related]
6. ASSESSMENT OF CELL SURFACE TARGETS IN METASTATIC PROSTATE CANCER: EXPRESSION LANDSCAPE AND MOLECULAR CORRELATES.
Ajkunic A; Sayar E; Roudier MP; Patel RA; Coleman IM; De Sarkar N; Hanratty B; Adil M; Zhao J; Zaidi S; True LD; Sperger JM; Cheng HH; Yu EY; Montgomery RB; Hawley JE; Ha G; Lee JK; Harmon SA; Corey E; Lang JM; Sawyers CL; Morrissey C; Schweizer MT; Gulati R; Nelson PS; Haffner MC
Res Sq; 2023 Dec; ():. PubMed ID: 38196594
[TBL] [Abstract][Full Text] [Related]
7. Oncogene-mediated metabolic gene signature predicts breast cancer outcome.
Aslan M; Hsu EC; Garcia-Marques FJ; Bermudez A; Liu S; Shen M; West M; Zhang CA; Rice MA; Brooks JD; West R; Pitteri SJ; Győrffy B; Stoyanova T
NPJ Breast Cancer; 2021 Oct; 7(1):141. PubMed ID: 34711841
[TBL] [Abstract][Full Text] [Related]
8. STK3 higher expression association with clinical characteristics in intrinsic subtypes of breast cancer invasive ductal carcinoma patients.
Rukhsana ; Supty AT; Hussain M; Lee Y
Breast Cancer Res Treat; 2024 Apr; ():. PubMed ID: 38592540
[TBL] [Abstract][Full Text] [Related]
9. Injectable Nano-in-Gel Vaccine for Spatial and Temporal Control of Vaccine Kinetics and Breast Cancer Postsurgical Therapy.
Liu T; Si X; Liu L; Ma S; Huang Z; Zhang Y; Song W; Zhang Y; Chen X
ACS Nano; 2024 Jan; 18(4):3087-3100. PubMed ID: 38235966
[TBL] [Abstract][Full Text] [Related]
10. Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer.
Jeon Y; Jo U; Hong J; Gong G; Lee HJ
BMC Cancer; 2022 Sep; 22(1):1014. PubMed ID: 36153494
[TBL] [Abstract][Full Text] [Related]
11. Targeting Trop-2 in cancer: Recent research progress and clinical application.
Qiu S; Zhang J; Wang Z; Lan H; Hou J; Zhang N; Wang X; Lu H
Biochim Biophys Acta Rev Cancer; 2023 Jul; 1878(4):188902. PubMed ID: 37121444
[TBL] [Abstract][Full Text] [Related]
12. A literature review of the promising future of
Wen Y; Ouyang D; Zou Q; Chen Q; Luo N; He H; Anwar M; Yi W
Ann Transl Med; 2022 Dec; 10(24):1403. PubMed ID: 36660684
[TBL] [Abstract][Full Text] [Related]
13. Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer.
Shastry M; Jacob S; Rugo HS; Hamilton E
Breast; 2022 Dec; 66():169-177. PubMed ID: 36302269
[TBL] [Abstract][Full Text] [Related]
14. Correlation of TROP-2 expression with clinical-pathological characteristics and outcome in triple-negative breast cancer.
Izci H; Punie K; Waumans L; Laenen A; Wildiers H; Verdoodt F; Desmedt C; Ardui J; Smeets A; Han SN; Nevelsteen I; Neven P; Floris G
Sci Rep; 2022 Dec; 12(1):22498. PubMed ID: 36577919
[TBL] [Abstract][Full Text] [Related]
15. TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC).
Parisi C; Mahjoubi L; Gazzah A; Barlesi F
Cancer Treat Rev; 2023 Jul; 118():102572. PubMed ID: 37230055
[TBL] [Abstract][Full Text] [Related]
16. Future potential targets of antibody-drug conjugates in breast cancer.
Corti C; Boscolo Bielo L; Schianca AC; Salimbeni BT; Criscitiello C; Curigliano G
Breast; 2023 Jun; 69():312-322. PubMed ID: 36996620
[TBL] [Abstract][Full Text] [Related]
17. Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings.
Lombardi P; Filetti M; Falcone R; Altamura V; Paroni Sterbini F; Bria E; Fabi A; Giannarelli D; Scambia G; Daniele G
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980630
[TBL] [Abstract][Full Text] [Related]
18. Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer.
Rugo HS; Tolaney SM; Loirat D; Punie K; Bardia A; Hurvitz SA; O'Shaughnessy J; Cortés J; Diéras V; Carey LA; Gianni L; Piccart MJ; Loibl S; Goldenberg DM; Hong Q; Olivo M; Itri LM; Kalinsky K
NPJ Breast Cancer; 2022 Aug; 8(1):98. PubMed ID: 36038616
[TBL] [Abstract][Full Text] [Related]
19. Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.
Rugo HS; Bardia A; Marmé F; Cortes J; Schmid P; Loirat D; Trédan O; Ciruelos E; Dalenc F; Pardo PG; Jhaveri KL; Delaney R; Fu O; Lin L; Verret W; Tolaney SM
J Clin Oncol; 2022 Oct; 40(29):3365-3376. PubMed ID: 36027558
[TBL] [Abstract][Full Text] [Related]
20. TROP2 translation mediated by dual m
Chen C; Chao Y; Zhang C; Hu W; Huang Y; Lv Y; Liu B; Ji D; Liu M; Yang B; Jiang L; Liang Y; Zhang H; Yuan G; Ying X; Ji W
Cancer Lett; 2023 Jul; 566():216246. PubMed ID: 37268280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
